{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T22:01:29Z","timestamp":1776808889792,"version":"3.51.2"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.vph.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,10,19]],"date-time":"2016-10-19T07:13:36Z","timestamp":1476861216000},"page":"14-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Aspirin, stroke and drug-drug interactions"],"prefix":"10.1016","volume":"87","author":[{"given":"Nicholas W.","family":"Russo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2016.10.006_bb0010","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","article-title":"Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0015","doi-asserted-by":"crossref","first-page":"630S","DOI":"10.1378\/chest.08-0720","article-title":"Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Albers","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.vph.2016.10.006_bb0020","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30468-8","article-title":"Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials","author":"Rothwell","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2016.10.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1603060","article-title":"Ticagrelor versus aspirin in acute stroke or transient ischemic attack","author":"Johnston","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2016.10.006_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2016.10.006_bb0045","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ijs.12129","article-title":"Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design","volume":"8","author":"Johnston","year":"2015","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0050","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/ijs.12538","volume":"10","author":"Krishnan","year":"2015","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0060","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0065","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000369778","article-title":"Aspirin plus clopidogrel as secondary prevention after stroke or transient ischemic attack: a systematic review and meta-analysis","volume":"39","author":"Zhang","year":"2013","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.vph.2016.10.006_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijs.12420","article-title":"Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial","volume":"10","author":"Toyoda","year":"2015","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0075","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1124\/dmd.114.060392","article-title":"Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review","volume":"42","author":"Yu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.vph.2016.10.006_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2016.06.003","article-title":"Dipyrone comedication in aspirin treated stroke patients impairs outcome","author":"Dannenberg","year":"2016","journal-title":"Vascul. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0100","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/194927b0","article-title":"Aggregation of blood platelets by adenosine diphosphate and its reversal","volume":"194","author":"Born","year":"1962","journal-title":"Nature"},{"key":"10.1016\/j.vph.2016.10.006_bb0105","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0140-6736(68)92013-8","article-title":"Effect of salicylates on human platelets","volume":"1","author":"O'Brien","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0110","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1073\/pnas.72.8.3073","article-title":"Acetylation of prostaglandin synthase by aspirin","volume":"72","author":"Roth","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2016.10.006_bb0115","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1073\/pnas.72.8.2994","article-title":"Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides","volume":"72","author":"Hamberg","year":"1975","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2016.10.006_bb0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0049-3848(80)90066-3","article-title":"Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects","volume":"17","author":"Patrono","year":"1980","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2016.10.006_bb0130","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1172\/JCI110576","article-title":"Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects","volume":"69","author":"Patrignani","year":"1982","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2016.10.006_bb0135","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/01.CIR.72.6.1177","article-title":"Clinical pharmacology of platelet cyclooxygenase inhibition","volume":"72","author":"Patrono","year":"1985","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.10.006_bb0140","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jacc.2008.10.047","article-title":"Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \u201cresistance\u201d","volume":"53","author":"Santilli","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2016.10.006_bb0145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.V69.1.180.180","article-title":"Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs","volume":"69","author":"Reilly","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.vph.2016.10.006_bb0150","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI108132","article-title":"The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein","volume":"56","author":"Roth","year":"1975","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.vph.2016.10.006_bb0155","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.12758","article-title":"Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation","volume":"165","author":"Machlus","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.vph.2016.10.006_bb0160","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1182\/blood-2011-06-359224","article-title":"Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target","volume":"119","author":"Pascale","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.vph.2016.10.006_bb0165","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2011.09.017","article-title":"Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia","volume":"129","author":"Dillinger","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2016.10.006_bb0170","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1538-7836.2012.04723.x","article-title":"The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes","volume":"10","author":"Rocca","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0175","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1160\/TH11-04-0216","article-title":"Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications","volume":"106","author":"Spectre","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0180","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jth.12832","article-title":"Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial","volume":"13","author":"Paikin","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0185","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1160\/TH09-07-0470","article-title":"Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery","volume":"103","author":"Brambilla","year":"2010","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0190","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1093\/eurheartj\/ehv366","article-title":"Platelet progenitors: the hidden drug target","volume":"36","author":"Rocca","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.vph.2016.10.006_bb0195","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jacc.2016.04.055","article-title":"Are immature platelets growing up?: toward a new marker of antiplatelet drug resistance","volume":"68","author":"Kleiman","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2016.10.006_bb0200","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2016.04.056","article-title":"Comparison of immature platelet count to established predictors of platelet reactivity during thienopyridine therapy","volume":"68","author":"Christian Stratz","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2016.10.006_bb0205","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJM198411083111902","article-title":"Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase","volume":"311","author":"Pedersen","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2016.10.006_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/jps.2600610312","article-title":"Absorption kinetics of aspirin in man following oral administration of an aqueous solution","volume":"61","author":"Rowland","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.vph.2016.10.006_bb0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3109\/03602537909046431","article-title":"Pharmacokinetics of salicylate in man","volume":"9","author":"Levy","year":"1979","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.vph.2016.10.006_bb0220","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.1986.tb05195.x","article-title":"Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man","volume":"21","author":"Rosenkranz","year":"1986","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0225","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1124\/jpet.106.110577","article-title":"Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol","volume":"319","author":"Tang","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0230","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.bcp.2008.10.005","article-title":"Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin","volume":"77","author":"Yang","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0235","doi-asserted-by":"crossref","first-page":"34820","DOI":"10.1074\/jbc.M111.267161","article-title":"Intracellular erythrocyte platelet-activating factor acetylhydrolase I inactivates aspirin in blood","volume":"286","author":"Zhou","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2016.10.006_bb0240","doi-asserted-by":"crossref","first-page":"11940","DOI":"10.1074\/jbc.M112.427674","article-title":"Aspirin hydrolysis in plasma is a variable function of butyrylcholinesterase and platelet-activating factor acetylhydrolase 1b2 (PAFAH1b2)","volume":"288","author":"Zhou","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2016.10.006_bb0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/01.STR.11.1.9","article-title":"Plasma acetylsalicylate and salicylate and platelet cyclooxygenase activity following plain and enteric-coated aspirin","volume":"11","author":"Ali","year":"1980","journal-title":"Stroke"},{"key":"10.1016\/j.vph.2016.10.006_bb0250","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/BF00558267","article-title":"Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function","volume":"35","author":"Bochner","year":"1988","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0255","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-001-0391-8","article-title":"Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans","volume":"57","author":"de la Cruz","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0260","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nsb0895-637","article-title":"The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase","volume":"2","author":"Loll","year":"1995","journal-title":"Nat. Struct. Biol."},{"key":"10.1016\/j.vph.2016.10.006_bb0265","doi-asserted-by":"crossref","first-page":"29372","DOI":"10.1074\/jbc.270.49.29372","article-title":"Arginine 120 of prostaglandin G\/H synthase-1 is required for the inhibition by nonsteroidal anti-inflammatory drugs containing a carboxylic acid moiety","volume":"270","author":"Mancini","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.vph.2016.10.006_bb0270","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1093-3263(01)00135-8","article-title":"Differential binding mode of diverse cyclooxygenase inhibitors","volume":"20","author":"Llorens","year":"2002","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.vph.2016.10.006_bb0275","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.3.4.383","article-title":"Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin","volume":"3","author":"Rao","year":"1983","journal-title":"Arteriosclerosis"},{"key":"10.1016\/j.vph.2016.10.006_bb0280","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0006-2952(80)90401-3","article-title":"Salicylate reverses in vitro aspirin inhibition of rat platelet and vascular prostaglandin generation","volume":"29","author":"Merino","year":"1980","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0285","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0090-6980(82)90123-X","article-title":"Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclooxygenase activity","volume":"23","author":"Livio","year":"1982","journal-title":"Prostaglandins"},{"key":"10.1016\/j.vph.2016.10.006_bb0290","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","article-title":"Cyclooxygenase inhibitors and the antiplatelet effects of aspirin","volume":"345","author":"Catella-Lawson","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2016.10.006_bb0295","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2007.02800.x","article-title":"Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis","volume":"6","author":"Hohlfeld","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0300","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ejphar.2013.09.032","article-title":"Drug\/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets","volume":"721","author":"Saxena","year":"2013","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0305","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1160\/TH12-07-0532","article-title":"High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs\u2014pharmacological mechanisms and clinical relevance","volume":"109","author":"Hohlfeld","year":"2013","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0310","doi-asserted-by":"crossref","first-page":"7069","DOI":"10.1021\/bi1003298","article-title":"Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers","volume":"49","author":"Sidhu","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.vph.2016.10.006_bb0315","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cpt.21","article-title":"Inhibition of antiplatelet effects of aspirin by nonopioid analgesics","volume":"97","author":"Hohlfeld","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0320","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bcp.12801","article-title":"Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation","volume":"81","author":"Ruzov","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0325","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(03)12509-3","article-title":"Effect of ibuprofen on cardioprotective effect of aspirin","volume":"361","author":"MacDonald","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0340","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","article-title":"Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials","volume":"382","author":"Bhala","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0345","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40262-014-0226-2","article-title":"Effects of alcohol on human carboxylesterase drug metabolism","volume":"54","author":"Parker","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.vph.2016.10.006_bb0350","doi-asserted-by":"crossref","first-page":"d2690","DOI":"10.1136\/bmj.d2690","article-title":"Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study","volume":"342","author":"Charlot","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2016.10.006_bb0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1160\/TH13-07-0542","article-title":"Use of proton pump inhibitors and the risk of coronary events in new users of low-dose acetylsalicylic acid in UK primary care","volume":"111","author":"Garcia Rodriguez","year":"2014","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.vph.2016.10.006_bb0360","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1046\/j.1365-2036.1997.00216.x","article-title":"Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats","volume":"11","author":"Giraud","year":"1997","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0365","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40256-013-0018-3","article-title":"Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole","volume":"13","author":"Offman","year":"2013","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.vph.2016.10.006_bb0370","first-page":"217","article-title":"Evaluation of the pharmacodynamics of acetylsalicylic acid 81mg with or without esomeprazole 20mg in healthy volunteers","volume":"12","author":"Andersson","year":"2012","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.vph.2016.10.006_bb0375","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/FJC.0b013e3181af6d9c","article-title":"Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study","volume":"54","author":"Adamopoulos","year":"2009","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0380","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials","volume":"374","author":"O'Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11739-013-1000-4","article-title":"Proton pump inhibitors and clopidogrel: an association to avoid?","volume":"9","author":"D'Ugo","year":"2014","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.vph.2016.10.006_bb0390","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1161\/CIRCOUTCOMES.114.001177","article-title":"Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when coadministered with dual antiplatelet therapy: systematic review","volume":"8","author":"Melloni","year":"2015","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.vph.2016.10.006_bb0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.thromres.2014.02.028","article-title":"Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?","volume":"134","author":"Hoirisch-Clapauch","year":"2014","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2016.10.006_bb0405","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002022","article-title":"Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding: a nationwide population-based cohort study in Taiwan","volume":"94","author":"Cheng","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.vph.2016.10.006_bb0410","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/ajg.2014.82","article-title":"Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis","volume":"109","author":"Anglin","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.vph.2016.10.006_bb0415","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1503\/cmaj.100912","article-title":"Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction","volume":"183","author":"Labos","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.vph.2016.10.006_bb0420","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0425","first-page":"185","article-title":"Aspirin does not interact with ACE inhibitors when both are given early after acute myocardial infarction: results of the GISSI-3 Trial","volume":"2","author":"Latini","year":"2000","journal-title":"Heart Dis."},{"key":"10.1016\/j.vph.2016.10.006_bb0430","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/00004872-200205000-00038","article-title":"Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy","volume":"20","author":"Zanchetti","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.vph.2016.10.006_bb0435","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S0140-6736(02)11138-X","article-title":"Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review","volume":"360","author":"Teo","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ahj.2009.11.009","volume":"159","author":"Levy","year":"2010","journal-title":"Am. Heart J."},{"key":"10.1016\/j.vph.2016.10.006_bb0445","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jacc.2005.05.060","article-title":"The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study","volume":"46","author":"Fossum","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2016.10.006_bb0450","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/erc.12.144","article-title":"Identifying determinants of variability to tailor aspirin therapy","volume":"11","author":"Rocca","year":"2013","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0455","doi-asserted-by":"crossref","first-page":"376721","DOI":"10.1155\/2012\/376721","article-title":"Variability in the responsiveness to low-dose aspirin: pharmacological and disease-related mechanisms","volume":"2012","author":"Rocca","year":"2012","journal-title":"Thrombosis"},{"key":"10.1016\/j.vph.2016.10.006_bb0460","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bmj.327.7427.1322","article-title":"Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study","volume":"327","author":"Curtis","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.vph.2016.10.006_bb0465","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jacc.2003.08.064","article-title":"The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin","volume":"43","author":"Kimmel","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.vph.2016.10.006_bb0470","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1161\/01.CIR.0000132491.96623.04","article-title":"Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population","volume":"109","author":"Garcia Rodriguez","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.10.006_bb0475","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1161\/01.CIR.0000087593.07533.9B","article-title":"Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs","volume":"108","author":"Kurth","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2016.10.006_bb0480","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/0091270007310379","article-title":"Effects of ibuprofen on the magnitude and duration of aspirin's inhibition of platelet aggregation: clinical consequences in stroke prophylaxis","volume":"48","author":"Gengo","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0485","doi-asserted-by":"crossref","first-page":"16830","DOI":"10.1073\/pnas.1406997111","article-title":"Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs","volume":"111","author":"Li","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.vph.2016.10.006_bb0490","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.2009.00243.x","article-title":"The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers","volume":"157","author":"Schuijt","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0495","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2710.2012.01373.x","article-title":"Influence of non-steroidal anti-inflammatory drugs on antiplatelet effect of aspirin","volume":"38","author":"Yokoyama","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0500","first-page":"935","article-title":"Effect of flurbiprofen and aspirin on platelet aggregation","volume":"10","author":"Pincus","year":"1991","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.vph.2016.10.006_bb0505","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2710.2011.01313.x","article-title":"Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic\/pharmacodynamic model","volume":"37","author":"Awa","year":"2012","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.vph.2016.10.006_bb0510","first-page":"1589","article-title":"Ibuprofen may abrogate the benefits of aspirin when used for secondary prevention of myocardial infarction","volume":"32","author":"Hudson","year":"2005","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2016.10.006_bb0515","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","article-title":"Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial","volume":"364","author":"Farkouh","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2016.10.006_bb0520","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1177\/0091270004266623","article-title":"Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers","volume":"44","author":"Van Ryn","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0525","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00228-012-1370-y","article-title":"Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: a placebo-controlled, ex vivo, serial placebo-controlled serial crossover study","volume":"69","author":"Meek","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.vph.2016.10.006_bb0530","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/art.30175","article-title":"Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences","volume":"63","author":"Anzellotti","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2016.10.006_bb0535","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2005.01.045","article-title":"Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects","volume":"45","author":"Capone","year":"2005","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189116302695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189116302695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T19:29:52Z","timestamp":1601148592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189116302695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":98,"alternative-id":["S1537189116302695"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2016.10.006","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aspirin, stroke and drug-drug interactions","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2016.06.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}